Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?

Name: Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
SKU: 21328
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Category: VOL 48 No. 3 Articles - 2018 Tags: adherence, antipsychotic, Heather Rozea, hospitalization, Jamie C. Barner, Lisa M. Mican, long-acting-injectable, readmission, Thomas J. Maestri

Description

Description

Original Research

Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
By Thomas J. Maestri, Lisa M. Mican, Heather Rozea, Jamie C. Barner

08-15_PB-48-3-2018-Maestri

Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?

Description

Original Research

Antipsychotic Induced Symptomatic Hyperprolactinemia

Psychopharmacology Bulletin VOL 47 No. 3, 2017 – Full Issue Stacked PDF

Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit

Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Title

Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?

Description

Original Research

Related products

Antipsychotic Induced Symptomatic Hyperprolactinemia

Psychopharmacology Bulletin VOL 47 No. 3, 2017 – Full Issue Stacked PDF

Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit

Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Title